Sesques, Pierre
Kirkwood, Amy A.
Kwon, Mi
Rejeski, Kai
Jain, Michael D.
Di Blasi, Roberta
Brisou, Gabriel
Gros, François-Xavier
le Bras, Fabien
Bories, Pierre
Choquet, Sylvain
Rubio, Marie-Thérèse
Iacoboni, Gloria
O’Reilly, Maeve
Casasnovas, René-Olivier
Bay, Jacques-Olivier
Mohty, Mohamad
Joris, Magalie
Abraham, Julie
Castilla Llorente, Cristina
Loschi, Mickael
Carras, Sylvain
Chauchet, Adrien
La Rochelle, Laurianne Drieu
Hermine, Olivier
Guidez, Stéphanie
Cony-Makhoul, Pascale
Fogarty, Patrick
Le Gouill, Steven
Morschhauser, Franck
Gastinne, Thomas
Cartron, Guillaume
Subklewe, Marion
Locke, Frederick L.
Sanderson, Robin
Barba, Pere
Houot, Roch
Bachy, Emmanuel
Article History
Received: 6 May 2024
Accepted: 19 July 2024
First Online: 6 August 2024
Declarations
:
: The protocol was approved by national ethic committee and the data protection agency, and the study was undertaken in accordance with the Declaration of Helsinki. DESCAR-T is registered under the ClinicalTrials.gov identifier NCT04328298.
: P.S: Honoraria, Advisory/Consultancy from Janssen, Roche, BMS, Chugai; Novartis and Kite/Gilead; A.K: Honoraria from Kite/Gilead; M.K: no conflict to declare; K.R. Kite/Gilead: Research Funding and travel support; Novartis: Honoraria; BMS/Celgene: Consultancy, Honoraria; Pierre-Fabre: travel support; MDJ: Consult/advisor for Kite/Gilead and Myeloid Therapeutics; research funding from Kite/Gilead, Incyte, and Loxo@Lilly; R.DB: Honoraria, travel support, and membership of advisory boards from Novartis,Kite/Gilead, Janssen, Pfizer, Celgene; G.B: Honoraria and travel fees from: Kite/Gilead, BMS, Incyte, Novartis; FX.G: Honoraria: Kite/Gilead, BMS, Milteny, Novartis.Consultancy, Honoraria; Amgen: Honoraria; Astrazeneca: Consultancy, Honoraria; F.LB: Takeda: Honoraria, Research Funding; Kite Gilead: Honoraria; Novartis: Honoraria; Celgene BMS: Research Funding; P.B. declares having received honoraria from Allogene, Amgen, BMS, Kit/Gilead, Incyte, Jazz Pharmaceuticals, Miltenyi Biomedicine, Nektar Novartis and Pierre Fabre; MTR: No COIs; G.I:Honoraria and travel support: Novartis, Kite/Gilead, Bristol-Myers Squibb, Abbvie, Autolus, Sandoz, Janssen, Miltenyi, AstraZeneca; MOR: no conflict to declare; ROC Honoraria for consultancy and advisory board:Roche, Takeda, BMS,MSD, Gilead/Kite, Janssen, ADC Therapeutics, Incyte; Research funding: Roche,Gilead, Takeda; JO.B: no conflict to declare; M.M.: No COIs; M.J: no conflict to declare; J.A: No COIs; CCLl: Honoraria from Gilead/Kite, Nektar Therapeutics; M.L: no conflict to declare; S.C: Kite/gilead: Consultancy and Membership on an entity's Board of Directors or advisory committees; Astrazeneca: Consultancy, Membership on an entity's Board of Directors or advisory committees and Research Funding; Abbvie; Other: Travelfees; Beigene: Membership on an entity's Board of Directors or advisory committees; Janssen Cilag: Membership on an entity's Board of Directors or advisory committees, Other: travel fees and Research Funding; A.C.: No COIs; L. DDLR: No COIs; O.H: No COIs; S.G: No COIs; P.CM: COIs; P.F: No COIs; S.LG: Honoraria, travel support, and membership of advisory boards from Novartis, Kite/Gilead, Janssen; F.M: Advisory boards pour Gilead, Novartis, BMS, épizyme, miltenyi,Abbvie, genmab, Roche, AstraZeneca; Consultancy: gilead, roche; Scientific lectures:Roche, Chugai; T.G: honoraria from Gilead/kite, Novartis, Takeda; G.C: Roche, Celgene-BMS: Consultancy; Danofi, Gilead, Novartis, Jansen, Roche, Celgene-BMS, Abbvie, Takeda: Honoraria; M.S. receives industry research support from Amgen, BMS/Celgene, Gilead, Janssen, Miltenyi Biotec, Novartis, Roche, Seattle Genetics and Takeda and serves as a consultant/advisor to AvenCell, CDR-Life, Ichnos Sciences, Incyte Biosciences, Janssen, Miltenyi Biotec, Molecular Partners, Novartis, Pfizer and Takeda. She serves on the speakers’ bureau at Amgen, AstraZeneca, BMS/Celgene, Gilead, GSK, Janssen, Novartis, Pfizer, Roche and Takeda; P.B. declares having received honoraria from Novartis, Kite Gilead, BMS Celgene and Abbvie; F.L.L: has a scientific advisory role with Kite, a Gilead Company, Novartis, Celgene/Bristol-Myers Squibb, GammaDelta Therapeutics, Wugen, Amgen, Calibr, and Allogene; is a consultant with grant options for Cellular Biomedicine Group, Inc.; and receives research support from Kite, a Gilead Company, Novartis, and Allogene; and reports that his institution holds unlicensed patents in his name in the field of cellular immunotherapy; R.S: No COIs; R.H: Honoraria from Bristol-Myers Squibb, Celgene, Gilead Sciences, Incyte, Janssen, Kite, MSD, Novartis and Roche; EB: Honoraria from Kite, a Gilead Company, Bristol Myers Squibb, Novartis, Pfizer, Incyte, ADC Therapeutics; personal fees from Kite, a Gilead Company, Bristol Myers Squibb, Novartis, Pfizer; research funding paid to institution from Amgen, BMS.; P.S: Honoraria, Advisory/Consultancy from Janssen, Roche, BMS, Chugai; Novartis and Kite/Gilead A.K: Honoraria from Kite/Gilead M.K: no conflict to declare K.R. Kite/Gilead: Research Funding and travel support; Novartis: Honoraria; BMS/Celgene: Consultancy, Honoraria; Pierre-Fabre: travel support MDJ: Consult/advisor for Kite/Gilead and Myeloid Therapeutics; research funding from Kite/Gilead, Incyte, and Loxo@Lilly. R.DB: Honoraria, travel support, and membership of advisory boards from Novartis,Kite/Gilead, Janssen, Pfizer, Celgene. G.B: Honoraria and travel fees from: Kite/Gilead, BMS, Incyte, Novartis FX.G: Honoraria: Kite/Gilead, BMS, Milteny, Novartis.Consultancy, Honoraria; Amgen: Honoraria; Astrazeneca: Consultancy, Honoraria. F.LB: Takeda: Honoraria, Research Funding; Kite Gilead: Honoraria; Novartis: Honoraria; Celgene BMS: Research Funding. P.B. declares having received honoraria from Allogene, Amgen, BMS, Kit/Gilead, Incyte, Jazz Pharmaceuticals, Miltenyi Biomedicine, Nektar Novartis and Pierre Fabre. MTR: No COIs. G.I:Honoraria and travel support: Novartis, Kite/Gilead, Bristol-Myers Squibb, Abbvie, Autolus, Sandoz, Janssen, Miltenyi, AstraZeneca MOR: no conflict to declare ROC Honoraria for consultancy and advisory board:Roche, Takeda, BMS,MSD, Gilead/Kite, Janssen, ADC Therapeutics, Incyte; Research funding: Roche,Gilead, Takeda JO.B: no conflict to declare M.M.: No COIs. M.J: no conflict to declare J.A: No COIs. CCLl: Honoraria from Gilead/Kite, Nektar Therapeutics M.L: no conflict to declare S.C: Kite/gilead: Consultancy and Membership on an entity's Board of Directors or advisory committees Astrazeneca: Consultancy, Membership on an entity's Board of Directors or advisory committees and Research Funding; Abbvie; Other: Travelfees; Beigene: Membership on an entity's Board of Directors or advisory committees; Janssen Cilag: Membership on an entity's Board of Directors or advisory committees, Other: travel fees and Research Funding A.C.: No COIs. L. DDLR: No COIs. O.H: No COIs. S.G: No COIs. P.CM: COIs. P.F: No COIs. S.LG: Honoraria, travel support, and membership of advisory boards from Novartis, Kite/Gilead, Janssen F.M: Advisory boards pour Gilead, Novartis, BMS, épizyme, miltenyi,Abbvie, genmab, Roche, AstraZeneca; Consultancy: gilead, roche; Scientific lectures:Roche, Chugai T.G: honoraria from Gilead/kite, Novartis, Takeda G.C: Roche, Celgene-BMS: Consultancy; Danofi, Gilead, Novartis, Jansen, Roche, Celgene-BMS, Abbvie, Takeda: Honoraria. M.S. receives industry research support from Amgen, BMS/Celgene, Gilead, Janssen, Miltenyi Biotec, Novartis, Roche, Seattle Genetics and Takeda and serves as a consultant/advisor to AvenCell, CDR-Life, Ichnos Sciences, Incyte Biosciences, Janssen, Miltenyi Biotec, Molecular Partners, Novartis, Pfizer and Takeda. She serves on the speakers’ bureau at Amgen, AstraZeneca, BMS/Celgene, Gilead, GSK, Janssen, Novartis, Pfizer, Roche and Takeda. P.B. declares having received honoraria from Novartis, Kite Gilead, BMS Celgene and Abbvie F.L.L: has a scientific advisory role with Kite, a Gilead Company, Novartis, Celgene/Bristol-Myers Squibb, GammaDelta Therapeutics, Wugen, Amgen, Calibr, and Allogene; is a consultant with grant options for Cellular Biomedicine Group, Inc.; and receives research support from Kite, a Gilead Company, Novartis, and Allogene; and reports that his institution holds unlicensed patents in his name in the field of cellular immunotherapy. R.S: No COIs. R.H: Honoraria from Bristol-Myers Squibb, Celgene, Gilead Sciences, Incyte, Janssen, Kite, MSD, Novartis and Roche EB: Honoraria from Kite, a Gilead Company, Bristol Myers Squibb, Novartis, Pfizer, Incyte, ADC Therapeutics; personal fees from Kite, a Gilead Company, Bristol Myers Squibb, Novartis, Pfizer; research funding paid to institution from Amgen, BMS.